Pitfalls in CTP: Why CTP Isn’t Always the Holy Grail in Acute Stroke Imaging

March 8, 2022
CTP is alluring in acute stroke and continues to become more available. But it's complicated. Learn the pitfalls and traps from a true expert in perfusion imaging.
0 Comments

When Should We Consider Restarting Anticoagulation in DVT, PE and Afib Patients? What Should I Tell the Family To Be on the Look-Out for Once They Are Discharged?

February 1, 2022
When patients need anticoagulation but have had an ICH or large ischemic stroke, when do we restart anticoagulation? When, if ever, is it safe?  
0 Comments

What Key Lessons Have I Learned Managing Hemorrhagic Bleeding in the ICU & Critical Care?

January 25, 2022
Intracerebral hemorrhages are challenging to manage and patients need immediate interventions to preserve life and limit morbidity. Lessons learned from the ICU and ED shed light on how to best care for these patients.
0 Comments

A Review of the Different Types of Anticoagulants and Their Clinical Applications

January 18, 2022
Anticoagulation in clinical practice is more common and more complicated every day. Understanding what they are, how they're used and when you'll see them in the clinical arena is critical. Two experts discuss their understanding of the landscape of anticoagulation and what you need to know about it.
0 Comments

Why Is the Extended Window Controversial and What Happened With the FDA?

September 7, 2021

Ever wonder why the FDA didn't approve the extended time window for tPA after ECASS3? Listen here to understand the discussion.

2 Comments
RSS
124678910Last
Categories
More Entries

Aug 3

What Is the Clinical Impact of the Genetic Polymorphism Observed with the Effectiveness of some P2Y12 Inhibitors?

Haemin Go posted on 8/3/2021

Moderator:W. Brian Gibler, MD FACEP, FACC, FAHA
Other Participants: Deepak L. Bhatt, MD, MPH and Natalie Kreitzer, MD, MS

Role of genetic polymorphism in TIA and stroke is and has been controversial, since the initial introduction of clopidogrel. Hear Drs. Bhatt and Kreitzer discuss the basics and background associated with the metabolism of the various agents, where we have come, the management of ACSand also for acute ischemic stroke, the role of dual antiplatelet therapy (DAPT), pivotal trials such as THALES, PIVOT, and THEMIS, and the importance of closely monitoring for a recurrent stroke, which happens with high frequency within the 1st month post a stroke.

0 Comments
Please login or register to post comments.